This article is more than 5 years old. Information may no longer be current.

Ozurdex offers better anatomic outcomes, similar visual acuity vs. anti-VEGF

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LONDON — For the treatment of patients with persistent diabetic macular edema, Ozurdex demonstrated better anatomic outcomes, but similar visual acuity results when compared with intravitreal Avastin, according to a speaker here.

“However, more eyes in the dexamethasone implant group lost vision,” Mark Gillies, MD, PhD, said at the Euretina Congress.

The multicenter, randomized clinical trial enrolled a total of 88 patients who were divided into two groups: those treated with intravitreal Avastin (bevacizumab, Genentech) and those treated with Ozurdex (dexamethasone 0.7 mg intravitreal implant, Allergan). Patients were followed for 1 year. The groups were homogeneous in terms of age, baseline visual acuity, gender distribution, duration of diabetes and IOP.

“The primary endpoint, a 10- or more letter gain, was achieved in a similar proportion, 40% vs. 42%, in the bevacizumab and dexamethasone implant groups,” Gillies said. “However, a loss of 10 or more letters was seen in 10% of the dexamethasone implant eyes, mostly due to un-operated cataract.”

At 12 months, central retinal thickness was significantly greater in the bevacizumab eyes, according to Gillies. Equally greater was the number of injections — on average, 8.6 compared with 2.7 — for the dexamethasone implant eyes.

Cataract surgery was the main adverse event, occurring in three of the dexamethasone implant eyes and in one bevacizumab-treated eye. The difference was not statistically significant, according to Gillies.

Increased IOP was seen in 26% of the dexamethasonetreated eyes, which received new glaucoma medications in 15% of the cases, Gillies said.

“It is a small study, and we are waiting for the results at 2 years to draw more interesting conclusions on steroid-induced cataract and cataract surgery,” Gillies said.

Disclosure: Gillies has no relevant financial disclosures.